Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Ginkgo Bioworks Holdings Inc (DNA) vs T-Mobile Us Inc (TMUS) Price & Performance

Ginkgo Bioworks Holdings IncTrade
T-Mobile Us IncTrade

Price performance (Past 24H)

Key statistics

Ginkgo Bioworks Holdings Inc vs T-Mobile Us Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $13 (market cap $763.64M), while T-Mobile Us Inc trades at $148.58 (market cap $183.76B). The key difference: T-Mobile Us Inc is far larger — about 240.6× Ginkgo Bioworks Holdings Inc's market cap, and T-Mobile Us Inc pays a 2.73% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and T-Mobile Us Inc for 84 Days on average.

DNATMUS
Market Cap
$763.64M$183.76B
Volume
3,204,1774,294,650
Sector
HealthMedia
52-Week High
$15.83$230.06
52-Week Low
$5.48$161.73
Typical Hold Time
7 Days84 Days
Enterprise Value
$865.59M$300.37B
Dividend Yield
—2.73%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $13.00, up 13.34% today, with a bullish technical signal from moving averages. The company shows strong gross margins of 68.04% but remains unprofitable with a -219.6% net margin. Recent news includes a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnership expansions, though revenue declined to $132M in 2026.

DNA presents high risk with significant losses and cash burn, but analyst sentiment is divided with equal buy/sell ratings. Investment appeal hinges on future profitability from recent partnerships and government contracts, while current financials and negative cash flow pose substantial downside risk.

T-Mobile Us Inc

T-Mobile US (TMUS) trades at $148.58, down 11.36% over 24 hours, reflecting recent market pressure. The stock shows strong fundamental health with revenue growth to $88.31B in 2025 and a net income margin of 11.45%. Analyst consensus is strongly bullish with a $231.10 price target, supported by a 15% dividend hike announced in September 2026. Technical indicators are mixed, with a bearish moving average signal but neutral oscillators, while recent news highlights AI-driven 5G advancements and a joint venture with AT&T and Verizon to expand coverage.

The outlook for TMUS is positive due to robust earnings beats, strategic initiatives, and solid cash flow, though risks include high debt levels and competitive pressures. Investors may find value in its growth trajectory and dividend increases, but should monitor debt management and industry competition closely.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

DNA
47% Buy53% Sell
Avg holding period · 7 Days
TMUS
53% Buy47% Sell
Avg holding period · 84 Days

Top news

Latest headlines on both assets

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA →

About T-Mobile Us Inc

Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.

Read more on TMUS →